Eco-design, collaboration, circular economy. These are the bywords of sustainability in biopharma.

Join Ryan Walker, Senior Director of Sustainability at Cytiva, and Aude Arkham, Global Head of Eco Design and Circular Economy at Sanofi, as they explore how eco-design and circular economy initiatives are shaping the future of healthcare.

We delve into challenges, achievements, and the transformational potential of sustainability efforts within biopharma. From Sanofi’s life cycle assessments to industry-wide data difficulties, this episode navigates the complex landscape of creating greener solutions without compromising innovation and compliance.

In this episode of "Discovery Matters," we dive into the powerful intersection of big data and artificial intelligence. Joined by Matej Macak, a partner from McKinsey, we unravel how AI and machine learning are revolutionizing our approach to finding new, effective medications.

With Tom Yankeelov, Professor of Biomedical Engineering, Diagnostic Medicine, Oncology at the University of Texas for Austin, we'll explore the "problem of averages" and much more.

What does 'the body as a bioreactor' mean? In this discussion how scientists use the body's machinery to produce therapeutic proteins. Scott Ripley, General Manager of Nucleic Acids at Cytiva, explains that traditional bioprocessing uses external bioreactors, while the new approach leverages the body's natural processes. This method offers benefits like longer protein half-life and the ability to express multiple proteins simultaneously. Justin Eyquem, assistant professor at University of California San Francisco, discusses the potential of in vivo CAR T cell therapy, which could simplify manufacturing and reduce costs. Both approaches face challenges in quality assurance and regulatory approval but hold promise for personalized and more effective treatments.